Peer-reviewed veterinary case report
New water-soluble paclitaxel dose tested for treating dog tumors
By von Euler, H et al.·Published in Veterinary and comparative oncology·2013·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with high-grade solid tumors received a new water-soluble formulation of paclitaxel (Paccal Vet) to treat their cancer. This treatment was given without the usual need for pre-medication and showed promising results, with 86% of the dogs responding positively within about two weeks. The dogs were treated with Paccal Vet for three or more cycles, and they experienced manageable side effects like temporary low blood cell counts. Overall, this new formulation appears to be a safe and effective option for dogs battling cancer.
People also search for: dog cancer treatment paclitaxel · high-grade tumors in dogs · side effects of paclitaxel for dogs
Abstract
A new formulation of water-soluble paclitaxel (Paccal® Vet) has been developed for canine cancer patients, without the need for pre-medication (traditionally required in non-water-soluble paclitaxel formulations). The objective of the study was to determine a clinically safe and efficacious dose of Paccal Vet and to estimate progression-free and overall survival and to evaluate single-dose pharmacokinetics in tumour-bearing dogs. A positive risk:benefit ratio was established for Paccal Vet administered at 150 mg m(-2) intravenous (IV) for three or more treatment cycles. Preliminary efficacy was demonstrated by best objective response rate (86%), median time to response (14 days) and median progression-free survival (131 days). Paccal Vet was associated with expected adverse events (AE) (e.g. myelosuppression), however the majority were transient, clinically silent and manageable. This is the first clinical report of a water-soluble formulation of paclitaxel suggesting successful administration and being safely used without pre-medication in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22404965/